Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesGastroenterologykernfamilyhealthcare H. pylori Coverage Update | O…
    Ask Trek AI about this page
    CurrentKern Family Health CarePolicy N/A

    Helicobacter pylori testing and treatment — Coverage Criteria

    Customize your policy alerts

    Sign up for all kernfamilyhealthcare policy alerts

    Know when kernfamilyhealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for providers on testing methods and recommended treatment regimens for H. pylori infection; describes covered diagnostic tests and antimicrobial regimens by Kern Family Health Care.

    Policy Summary
    PayerKern Family Health Care
    PolicyHelicobacter pylori testing and treatment — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the chosen diagnostic test (urea breath, stool antigen, or biopsy) and note use of interfering medications when treating H. pylori.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >90%Urea Breath / Stool antigen sensitivity
    14 daysTypical regimen duration
    500 mg BIDClarithromycin dosing
    1 g BIDAmoxicillin dosing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for H. pylori Testing and Treatment

    Covered H. pylori treatment regimens

    Covered when using recommended regimens.

    Preferred regimens: Bismuth Quadruple Therapy, Concomitant Quadruple Therapy, and Triple Therapy are covered.

    Document regimen choice and durations as listed.

    Bismuth Quadruple Therapy (example dosing): Bismuth subsalicylate 262 mg QID + metronidazole 500 mg TID–QID or doxycycline 100 mg BID + PPI (omeprazole or pantoprazole) BID; duration 14 days.14 days

    Select bismuth combination components per patient tolerance and allergies.

    Concomitant Quadruple Therapy (example dosing): Clarithromycin 500 mg BID + amoxicillin 1 g BID + metronidazole 500 mg BID + PPI (omeprazole or pantoprazole) BID; duration 14 days.14 days

    Used as a preferred non-bismuth quadruple regimen.

    Triple Therapy (example dosing): Clarithromycin 500 mg BID + amoxicillin 1 g BID + PPI (omeprazole or pantoprazole) BID; duration 14 days.14 days

    Consider local clarithromycin resistance; triple therapy effectiveness is reduced where clarithromycin resistance is high.

    Documentation: Providers should document the chosen regimen and confirm use of a recommended regimen and durations. Document the diagnostic test used (urea breath, stool antigen, or biopsy) and any interfering medications (PPIs, bismuth, antibiotics) that could affect testing.

    Serology is not appropriate for documenting eradication or distinguishing active versus past infection.

    Serology testing for Helicobacter pylori is not appropriate to document eradication or to distinguish active infection from past exposure. The policy follows the source guidance that serologic assays "lack specificity and sensitivity," cannot differentiate active versus past infections, and "are not able to be used for documenting eradication." Providers should therefore use noninvasive tests with demonstrated accuracy (urea breath test or stool antigen) or biopsy-based testing when documenting eradication.

    Provider Actions, Documentation, and Prescribing Guidance

    Prior Authorization

    Pharmacologic regimen coverage — covered regimens and dosing/duration notes

    Kern Family Health Care covers Bismuth Quadruple Therapy, Concomitant Quadruple Therapy, and Triple Therapy for H. pylori as specified in the policy. Regimen-specific dosing and 14-day durations are provided (e.g., bismuth subsalicylate 262 mg QID + metronidazole 500 mg TID–QID or doxycycline 100 mg BID, plus a PPI BID for 14 days; clarithromycin 500 mg BID with amoxicillin 1 g BID and PPI BID for 14 days for triple/concomitant regimens).

    • Bismuth Quadruple Therapy: bismuth subsalicylate 262 mg QID + metronidazole 500 mg TID–QID or doxycycline 100 mg BID + PPI (omeprazole or pantoprazole) BID — duration 14 days. [See dosing details in source]
    • Concomitant Quadruple Therapy: clarithromycin 500 mg BID + amoxicillin 1 g BID + metronidazole 500 mg BID + PPI BID — duration 14 days.
    • Triple Therapy: clarithromycin 500 mg BID + amoxicillin 1 g BID + PPI BID — duration 14 days.
    • Kern Family Health Care explicitly states it covers all these regimens.
    Step Therapy

    Definitions and Test Performance

    inv-08: Urea Breath Test / Stool Antigen Test — noninvasive diagnostics with >90% sensitivity and specificity
    Test typesUrea Breath Test and Stool Antigen Test (noninvasive)
    Performance>90% sensitivity and specificity
    Practical considerationsStool antigen test requires no special equipment and may be less expensive than the breath test
    Alternate diagnosticEndoscopy with biopsy is available but typically slower and more expensive
    Interfering factorsProton pump inhibitors, bismuth products, and antibiotics can interfere with breath, stool, and urease biopsy tests
    inv-09: Serology for H. pylori — blood antibody testing lacks specificity/sensitivity and cannot distinguish active vs past infection; not for documenting eradication

    Background

    H. pylori is the most common cause of peptic ulcers; eradication promotes gastric healing and prevents recurrence of gastric or duodenal ulcers. Noninvasive tests — the urea breath test and stool antigen test — have >90% sensitivity and specificity and are preferred for diagnosis and post-treatment confirmation when interference from medications has been managed. Endoscopic biopsy is also available but is more resource intensive. Proton pump inhibitors, bismuth products, and antibiotics can interfere with breath, stool, and urease biopsy tests, so timing and documentation of these medications are important when testing for eradication.

    Policy Summary
    PayerKern Family Health Care
    PolicyHelicobacter pylori testing and treatment — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the chosen diagnostic test (urea breath, stool antigen, or biopsy) and note use of interfering medications when treating H. pylori.
    SourceLink
    On This Page
    Coverage Criteria for H. pylori Testing and TreatmentProvider Actions, Documentation, and Prescribing GuidanceDefinitions and Test PerformanceBackground

    Step therapy — none specified; preferred regimens listed

    No step therapy or prerequisite failure requirements are specified in the policy; the document identifies Bismuth Quadruple Therapy, Concomitant Quadruple Therapy, and Triple Therapy as the preferred regimens.

    • Clarifies that clarithromycin triple therapy was previously preferred but is now less effective due to clarithromycin resistance; current preferred regimens are bismuth quadruple, concomitant quadruple, and triple therapy.
    Documentation Required

    Testing documentation — record test choice and interfering medications/timing

    Document the diagnostic test used (urea breath test, stool antigen, or biopsy) and record use of any medications that can interfere with test accuracy — specifically proton pump inhibitors, bismuth products, or antibiotics — and timing relative to testing.

    • Specify which test was chosen (urea breath, stool antigen, or endoscopic biopsy).
    • Note current or recent use of PPIs, bismuth, or antibiotics that may interfere with breath, stool, and urease biopsy tests and the timing of those agents relative to testing.
    Denial Risk

    Serology limitations — inappropriate for eradication testing; may be denied

    Serology is not appropriate for documenting eradication or distinguishing active versus past H. pylori infection and may be denied if used for eradication testing.

    • Serology lacks specificity and sensitivity and cannot differentiate active from past infection.
    • Serology should not be used to document eradication; use urea breath, stool antigen, or biopsy instead.
    Test typeSerology (blood antibody testing)
    LimitationsLacks specificity and sensitivity
    Cannot distinguishUnable to differentiate active versus past H. pylori infection
    Not for eradication documentationSerology should not be used to document eradication
    ImplicationUse of serology for eradication or differentiating active vs past infection may be inappropriate for clinical decision-making